Vor Biopharma Inc. cash flow to debt ratio of -4.76K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Vor Biopharma Inc.'s free cash flow has decreased 43.81% from $-99.89M last year to $-143.65M, signaling decreasing performance

Vor Biopharma Inc.'s debt to equity ratio is -0.01, signaling that the company spent its equity and risk bankruptcy.

Vor Biopharma Inc.'s debt to equity ratio is -0.01, signaling that the company spent its equity and risk bankruptcy.

Vor Biopharma Inc. has a net cash position, so leverage is healthy.

Vor Biopharma Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Vor Biopharma Inc. has insufficient data to evaluate this check.

Vor Biopharma Inc.'s short-term assets of $458.11M exceed its short-term liabilities of $25.17M

Vor Biopharma Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Vor Biopharma Inc.'s return on equity of -91.63%, is lower than 15.00%, indicating bad performance

Vor Biopharma Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Vor Biopharma Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Vor Biopharma Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Vor Biopharma Inc. has negative free cash flow, indicating cash burn

Vor Biopharma Inc.'s yearly earnings has decreased 495.29% since last year from $-116.91M to $-695.98M, signaling decreasing performance

Vor Biopharma Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -32.21% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Vor Biopharma Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Vor Biopharma Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Vor Biopharma Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Vor Biopharma Inc. has insufficient data to evaluate this check.

Vor Biopharma Inc. has an earnings yield of 49.47%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Vor Biopharma Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Vor Biopharma Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Vor Biopharma Inc. has insufficient data to evaluate this check.

Vor Biopharma Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Vor Biopharma Inc. has negative shareholder equity; price-to-book is not meaningful and the check fails

Vor Biopharma Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue